44 results about "Tetracaine hydrochloride" patented technology

The invention belongs to the technical field of medicine, and relates to pontocaine lipidosome gel and a preparation method thereof. The pontocaine gel comprises pontocaine, propping agent and other lipide ingredients, wherein, the content of the pontocaine is 0.5%-1.0%. The preparation method comprises the following steps: (1) the pontocaine and other lipide ingredients are dissolved by organic solvent, and then the organic solvent is removed for hydration, so that blank lipidosome solution is manufactured; (2) dug-loading by ammonium sulphate gradient method : after being dialyzed, the blank lipidosome is added with pontocaine aqueous solution and brooded by water bath to be made into pontocaine lipidosome; (3) carbomer is weighed and is dipped in the prepared part of the pontocaine lipidosome, sealed and placed to stay over the night, the mixture is added with the rest pontocaine lipidosome and added with other auxiliary materials at last to be stirred evenly, so that the pontocaine lipidosome gel is prepared. In the invention, the pontocaine lipidosome gel is made of pontocaine, so as to not only achieve the effect of slow release, but also reduce the toxic side effect of the medicine.

The invention provides an oral ulcer mucoadhesive film and a preparation method thereof. The oral ulcer mucoadhesive film is prepared by honeysuckle flower, menthol, vitamin B [2], borneol, tetracaine hydrochloride, sorbic acid, prednisone acetate, chlortetracycline hydrochloride, glycerin, stevioside, ethanol PVA 17-88 and purified water. Compared with the prior art, the film has good flexibility and tensile strength, can rapidly being expended and dissolved when meets water, a high-density protection drug film layer is formed on the oral cavity mucous membrane, and the effect for rapidly relieving swelling and pain with long term can be reached; oral cavity mucous membrane is employed for direction drug administration, the drug can be directly effected on the disease, simultaneous treatment of principal and subordinate symptoms can be reached, curative effect is fully performed; a lattice impression technology is employed on the technology, administration with divided dose is accurate, curative effect is increased, quality is stable, the oral ulcer mucoadhesive film has no toxic and side effect for oral cavity, and is safe and effective; and has the advantages of small volume, light weight, and convenient carrying and usage.

The invention relates to a tetracaine hydrochloride endoscope lubricant and a preparation method thereof. The tetracaine hydrochloride endoscope lubricant comprises a component with the following concentration as shown in the specification. The tetracaine hydrochloride endoscope lubricant has the characteristics of being simple and convenient in taking method and small in application dose, so that the operation steps before an operation are greatly simplified, and the tetracaine hydrochloride endoscope lubricant is suitable for medical staff to extensively popularize and use. While a testee is narcotized, the tetracaine hydrochloride endoscope lubricant is beneficial to penetration and guide-out of a gastroscope, so that the pains of a patient are greatly relieved; more importantly, the tetracaine hydrochloride endoscope lubricant has more excellent effects in eliminating and restraining foams, and can effectively remove foams generated in the stomach, so that the medical staff can obtain more clear observation view, and the diagnosis accuracy for disease of digestive tracts is greatly improved.

The invention discloses epidermal anesthesia gel and a preparation method thereof. The epidermal anesthesia gel is composed of, by weight, 3-5 parts of tetracaine hydrochloride, 1-3 parts of thickener, 0.5-0.7 part of pH regulator and 92-95 parts of purified water, the thickener is xanthan gum, and the pH regulator is sodium hydroxide. The preparation method includes the following steps: adding the purified water into a mixing bucket, adding the pH regulator into the purified water, and stirring uniformly to form a solution a; mixing the thickener and tetracaine hydrochloride well, adding the thickener and tetracaine hydrochloride into the solution a in a stirring state, stirring until uniform paste is formed, and filling. The epidermal anesthesia gel can replace similar imported drug, has better performance, can lower medication burden of Chinese people and is quick in effect appearing, little in side effect, wide in using range, long in acting time, simple in preparation process, high in industrialized production efficiency and low in cost, and anesthesia effect on most patients can reach 4-6h after single dose.

The invention relates to a tetracaine hydrochloride crystal and a preparation method thereof, and a composition containing tetracaine hydrochloride and a preparation method thereof. The tetracaine hydrochloride crystal has characteristic peaks in the X-ray powder diffractogram at the following 2theta diffraction angles: 6.7 degrees, 11.0 degrees, 13.5 degrees, 14.2 degrees, 14.7 degrees, 17.4 degrees, 18.6 degrees, 19.7 degrees, 20.2 degrees, 21.0 degrees, 21.8 degrees, 23.2 degrees, 23.8 degrees, 24.4 degrees, 24.9 degrees, 26.1 degrees, 27.1 degrees, 28.9 degrees, 30.5 degrees, 32.2 degrees, 33.6 degrees, 34.1 degrees, 34.8 degrees, 35.8 degrees, 38.9 degrees, 39.4 degrees and 40.0 degrees. The crystal purity is 99.8% above, and no organic solvent resides; and the composition prepared from the crystal has the advantages of favorable dissolvability, high stability and high medical safety.

The invention provides a tetracaine hydrochloride oral cavity anesthetic liquid. The tetracaine hydrochloride oral cavity anesthetic liquid is prepared from the following raw materials: tetracaine hydrochloride, chlorhexidine acetate, glycerol, peppermint oil and saccharin sodium. The invention further provides a preparation method of the tetracaine hydrochloride oral-cavity anesthetic liquid. The preparation method of the tetracaine hydrochloride oral-cavity anesthetic liquid comprises the following steps: (1) weighing the tetracaine hydrochloride and the chlorhexidine acetate in proportion, adding the tetracaine hydrochloride and the chlorhexidine acetate in distilled water at 100 DEG C, stirring until the tetracaine hydrochloride and the chlorhexidine acetate are dissolved, and standing so as to reduce the temperature to 50-60 DEG C to obtain a solution 1; and (2) mixing the peppermint oil with the same amount of tween-80 and then adding the mixture, the glycerol and the saccharin sodium into the solution 1 obtained in the last step, stirring until the glycerol and the saccharin sodium are dissolved, adding distilled water at 50-60 DEG C till requisite amount, and uniformly mixing to obtain the tetracaine hydrochloride oral-cavity anesthetic liquid. The tetracaine hydrochloride oral cavity anesthetic liquid disclosed by the invention has the beneficial effects that an oral cavity surface anesthetic effect can be sufficiently perfected for a patient subjected to awake tracheal intubation, a patient with oral cavity operation or a patient subjected to other associated operations of an oral cavity, the comfort level of the patient in an awake tracheal intubation process, surgical procedures or other associated operations is improved, and the pains of the patient are reduced to the greatest extent.

The invention provides a novel tetracaine hydrochloride pharmaceutical composition for injection and a preparation method of the pharmaceutical composition. A small amount of tartaric acid is used in a prescription, so that the stability of the product is remarkably improved, the product can be further stored stable for a long time under the condition of high temperature, high humidity and light, and the storage time is prolonged. The preparation process is simple and free from nitrogen charge operation, and the demand on the production equipment is reduced, so that the invention is more suitable for production on a large scale.

The invention discloses a tetracaine hydrochloride oral effervescent tablet. The tetracaine hydrochloride oral effervescent tablet is prepared from the following components including tetracaine hydrochloride, tartaric acid, sodium bicarbonate, aspartame, sodium chloride, mannitol, an adhesive and a lubricant. A preparation method of the tetracaine hydrochloride oral effervescent tablet comprises the following steps: respectively sieving the tartaric acid, the sodium bicarbonate, the mannitol, the aspartame and the sodium chloride, adding into a mixer together, stirring, then adding the tetracaine hydrochloride into the mixture, fully stirring, then adding a PVP absolute ethyl alcohol solution, fully stirring to prepare a soft material, sieving the soft material, drying, carrying out size stabilization, adding PEG6000, fully stirring, and tabletting to obtain the tetracaine hydrochloride oral effervescent tablet. The tetracaine hydrochloride oral effervescent tablet has the remarkable effects that after the tablet is put into an oral cavity, a great amount of bubbles are immediately generated under the action of an effervescent disintegrating agent to enable the tablet to be rapidly disintegrated and melted, and the tetracaine hydrochloride is widely and directly contacted with the oral cavity part, so that the local anesthetic action is better exerted, the comfort degree of a patient in the awake intubation process is increased, and pains of the patient are reduced to the maximum.

The invention belongs to the field of medical technology, and relates to a pharmaceutical composition for treating dermatitis and a preparation method thereof. The pharmaceutical composition for treating dermatitis is prepared by mixing the following materials: glycerin monostearate, PEG-100 stearate, liquid paraffin, emulsifier 60, stearic acid, glycyrrhetinic acid, DC250dimethicone, lauryl potassium phosphate, glycerol, diphenhydramine hydrochloride, purified water, propylene glycol, menthol, camphor and tetracaine hydrochloride. Based on the common biochemical character and symptom of the dermatitis, diphenhydramine antihistamine is added in the formula, so that the histamine level of inflammatory response on a dermatitis part is reduced. Besides, the licorice extract of glycyrrhetinic acid is added, so that the skin is stimulated to secrete adrenal cortex hormone at the physiological level, and the phenomenon that the cortical hormone level is higher than the physiological level which can be borne by the skin of the human body as the adrenal cortex hormone is externally used and supplemented is avoided.

The invention discloses a plastering film for treating ulcerative stomatitis and its preparation, wherein the medicament is prepared from honeysuckle flower, menthol, vitamin B2, boneol, tetracaine hydrochloride, sorbic acid, prednisone acetate, chlortetracycline hydrochloride, glycerin, stevioside, ethanol, polyvinyl alcohol PVA17-88 and purified water.

The invention discloses an anti-adhesion hernia tablet with an analgesic effect and a preparation method thereof, and provides an anti-adhesion hernia tablet with an analgesic effect for solving the problem that existing hernia tablets can cause adhesion and chronic pain to patients. The hernia tablet is composed of a hernia tablet substrate, an electrospun nanofiber membrane wrapping the hernia tablet substrate and microspheres wrapped in the electrospun nanofiber membrane, and the electrospun nanofiber membrane on the surface of the hernia tablet and the the microspheres are made of a PLGA material which has degradability and biocompatibility and also has a good anti-adhesion effect; meanwhile, a high-penetrating anesthetic, namely tetracaine hydrochloride is embedded in the microsphereson the surface of the hernia tablet, so that the hernia tablet also has an analgesic effect. In summary, the hernia tablet can solve the problem that existing hernia tablets can cause adhesion and chronic pain to patients. The invention also provides a preparation method of the hernia tablet.

The invention discloses a patch for treating oral ulcer. Every 625 patches are prepared from the following raw materials: 0.5*10<6> to 2*10<6>IU of neomycin sulfate, 0.5 to 2g of clotrimazole, 0.1 to 1g of tetracaine hydrochloride, 1 to 8mg of betamethasone, 2 to 10g of borneol, 2 to 10g of mannitol, 2 to 10g of sodium carboxymethylcellulose, 10 to 20mL of ethanol, 0.05 to 2mL of glycerol and 10 to 20mL of purified water. The medicine is simple in component and low in cost, has an obvious curative effect on patients suffering from recurrent oral ulcer and does not have any toxic or side effects.

The invention discloses a pharmaceutical preparation for treating pharyngeal ulcer. The pharmaceutical preparation is prepared from 0.05-0.15g of garlic extract, 0.5-1.25g of aloe extract, 0.5-1.0g of tetracaine hydrochloride, 0.5-1.0g of tragacanth, 50-70ml of glycerin and 30-50ml of purified water. The preparation method comprises the following steps: adding the aloe extract and tragacanth into glycerin for grinding, and wetting; adding the garlic extract and the tetracaine hydrochloride into the purified water, boiling and dissolving; uniformly mixing, grinding into colloid, supplementing the residual purified water, stirring into a homogeneous phase, split charging, sterilizing at the temperature of 100 DEG C for 30 minutes, thereby obtaining the gel so as to be applied to a pharmaceutical preparation for treating pharyngeal ulcer. According to clinical verifications of 80 cases, the pharmaceutical preparation is exact in curative effect of treating pharyngeal ulcer and does not have any adverse reaction. The pharmaceutical ingredients can be effectively remained at the ulcer part for a long time, the curative effect is reliable, the medicine can be daubed by non-professional persons, the inconvenience that nebulizer treatment can be performed by virtue of medical equipment only is avoided, and the pharmaceutical preparation is simple and feasible to use and safe.

The invention discloses a tetracaine hydrochloride pharmaceutical composition. The tetracaine hydrochloride pharmaceutical composition is prepared by the steps: purifying a crude product of 4-(butylamino) benzoic acid-2-(dimethylamino) ethyl ester hydrochloride, mixing the purified 4-(butylamino) benzoic acid-2-(dimethylamino) ethyl ester hydrochloride with polyethylene glycol, peppermint oil and grape seed oil sequentially, thereby obtaining the product. The invention also discloses a method for preparing the tetracaine hydrochloride pharmaceutical composition. The method comprises the following steps: purifying the crude product of 4-(butylamino) benzoic acid-2-(dimethylamino) ethyl ester hydrochloride, thereby obtaining a purified product; and mixing polyethylene glycol and the purified product for stirring, adding the peppermint oil and grape seed oil, stirring, performing vacuum concentration and cooling, thereby obtaining the tetracaine hydrochloride pharmaceutical composition. The tetracaine hydrochloride pharmaceutical composition prepared by the invention has the advantages of high purity, good lubricating property, small dosage and excellent anesthetic effect.

The invention relates to a liquid gel dressing for treating kysthitis and its preparation method. The liquid gel dressing is prepared from nano-silver, glycerinum, ethylparaben, benzalkonium bromide,N-isopropylacrylamide, polyethylene glycol, oleum menthae, tetracaine hydrochloride, ureidohydantoin, chitosan quaternary ammonium salt, growth factor, human-like collagen, citric acid, disodium hydrogen phosphate, coptis chinensis, polygonum cuspidatum, gallnut, hairyvein agrimony, pulsatilla chinensis, clove, sanguisorba officinalis and others. The liquid gel dressing can be used for treating kysthitis.

The invention relates to lubricating gel capable of relieving spasm and pain. The gel is prepared from 0.5-0.8% of hydroxypropyl methyl cellulose, 0.8-1.2% of tetracaine hydrochloride, 1.0-2.0% of polyethylene glycol, 0.01-5% of chlorhexidine acetate, 0.01-5% of triamcinolone, 0.01-5% of racanisodamine and the balance purified water. Meanwhile, the gel has multiple effects including that a lubricating function is achieved when cannulas are introduced into human body cavities and endoscopic surgical dry tools enter the human body, local anesthesia is conducted on skin mucosae, and foam of the cavities is removed to relieve the spasm and pain and alleviate mucosa inflammatory edema caused by cannula insertion and other operation. Not only can the examination and surgery time be saved, but also the psychological pain and physical pain of a patient can be alleviated, the success rates of examination and surgery are increased at the same time, damage caused by surgery or instrument operation to the mucosae is reduced, and the lubricating gel has a significant clinical meaning.

The invention belongs to the technical field of biological pharmacy, and discloses a skin anesthesia cream for western surgery and a preparation method thereof. The skin anesthesia cream is prepared from the following components of 10mg of lidocaine hydrochloride, 16mg of tetracaine hydrochloride, 14mg of prilocaine, 54mg of thickener, 20mg of wetting agent, 16mg of azone, 9mg of cason, 560ml of distilled water, and 28mg of lidocaine, wherein the thickener is a carboxymethylcellulose and polyethylene glycol 6000 mixture; the wetting agent is a propanediol and glycerin mixture. The skin anesthesia cream for western surgery has the advantages that the permeation function on mucosa and skin is strong, the effect is quickly taken, the irritation or allergy reaction is avoided, the certain aging is maintained, and the cost is low; a preparation method of a novel surface anesthesia cream is provided.

The invention discloses a compound tetracaine hydrochloride membrane and a preparation method thereof. The compound tetracaine hydrochloride membrane is prepared from tetracaine hydrochloride, gentamicin sulfate, hydrocortisone, sodium carboxymethylcellulose (CMC-Na), polyvinyl alcohol (PVA), glycerol and purified water. When a drug is added to a film-forming material, an FLUKO FA25 high-shear dispersing emulsifying machine is used for stirring, and compared with traditional manual stirring, a medicine liquid is uniform and fine in quality, and the working efficiency is high. In a membrane laying process, an electric membrane laying device is used to replace an original manual membrane laying manner, thus solving the conditions that the production efficiency is low, the thickness of a medical membrane is not uniform, a weight difference limit degree in quality inspection is not in conformity with regulations, and the like. The electric membrane laying device is simple and easy to operate, can accurately control the membrane laying rate and the thickness of films, is uniform in membrane laying, is good in flatness, is controllable in thickness, and enables the production efficiencyto be greatly improved. The compound tetracaine hydrochloride membrane is locally applied to treat oral ulcer, has the effects of diminishing inflammation and stopping pain, is strong in pertinence, is substantial in curative effect, is easy for patients to accept, and is an ideal medicine for treating the oral ulcer.

The invention relates to the technical field of medicines, in particular to a medicine for treating dermatitis and a preparation method thereof. The medicine for treating dermatitis is formed by blending following raw materials including, by weight, oil phase components comprising 2-6 parts of glyceryl monostearate, 2-6 parts of PEG-100 stearate, 2-5 parts of stearic acid, 0.5-1 part of glycyrrhetinic acid, 1-3 parts of lanolin and 2-4 parts of shea butter, aqueous phase components comprising 3-6 parts of glycerol, 0.8-1.2 parts of diphenhydramine hydrochloride and 55-60 parts of purified water, and pharmaceutical active components comprising 2-3 parts of chlorpheniramine maleate, 4-6 parts of propylene glycol, 1-2 parts of menthol, 1-2 parts of camphor and 0.1 part of tetracaine hydrochloride. The medicine has the beneficial effects that the main symptoms of dermatitis are itching, skin inflammation and elevated histamine level, and the components of the medicine are designed specific to the three symptoms of dermatitis correspondingly, so that the medicine has a coordinated effect on curing dermatitis.